Amer Zeidan shared a post on X:

“I have to say I find MRD literature increasingly confusing as it pertains to decision-making. Would you NOT transplant a high VAF FLT3-ITD AML patients if they clear a concurrent NPM1 mutation after induction or first consolidation?”

View additional information.
Source: Amer Zeidan/X

Amer Zeidan is an Associate Professor of Medicine (Hematology) at Yale University. He is also the medical director of Hematology Early Therapeutics Research, the leader of the Myeloid Malignancies DART (Disease Aligned Research Team), and the director of Continuing Medical Education (CME) at the Hematology division and chairs the Protocol Review Committee (PRC) at Yale Cancer Center. Dr. Zeidan is a well-known leukemia researcher with a special focus on targeted therapies and immunotherapy for myeloid malignancies, and a social media influencer in the field of blood cancer.

MRD literature typically refers to literature related to Minimal Residual Disease (MRD) in the context of cancer. MRD refers to the small number of cancer cells that may remain in the body during or after treatment, even when the patient is in remission. Detecting and monitoring MRD is crucial because these residual cancer cells can potentially lead to relapse. MRD literature encompasses research articles, clinical studies, reviews, and other publications focused on understanding, detecting, monitoring, and treating minimal residual disease in various types of cancer.